About: chronic hepatitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: chronic hepatitis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

form of clinical course of hepatitis

Attributes	Values
rdf:type	Item
description	form of clinical course of hepatitis (en) форма клінічного перебігу гепатиту (uk)
health specialty	wds:Q62019625-18d75d34-4d96-9076-dae5-02bedc5f5f71 wds:Q62019625-1f8c463b-4e0f-1a81-682f-f33818434b58 wds:Q62019625-7747d8e3-400c-82ea-18ca-8d5e646ea172
ICD-10	wds:Q62019625-8fcf8f57-4daf-460a-f2f9-de85945b043c
health specialty	gastroenterology hepatology infectious diseases
ICD-10	K73.9
rdfs:label	chronic hepatitis (en) chronická hepatitida (cs) hépatite chronique (fr) хронічний гепатит (uk)
skos:prefLabel	chronic hepatitis (en) chronická hepatitida (cs) hépatite chronique (fr) хронічний гепатит (uk)
name	chronic hepatitis (en) chronická hepatitida (cs) hépatite chronique (fr) хронічний гепатит (uk)
LiverTox ID	wds:Q62019625-1B5AE019-7F77-42D3-94DC-B9D8127A31D1
LiverTox ID	Phenotypes_chron
instance of	wds:Q62019625-83dd8846-45ae-1e78-3c68-052b8230c0c9
NL CR AUT ID	wds:Q62019625-2E080D9F-2872-469B-B005-8F67C29374F2
instance of	disease
NL CR AUT ID	ph171325
subclass of	wds:Q62019625-7072c83a-4c9e-68e6-4376-e0d34cccf835
subclass of	hepatitis
Medical Dictionary...ory Activities ID	wds:Q62019625-03BEC283-C5AF-4C99-BF0D-9FC1A9F636DC
ICD-9 ID	wds:Q62019625-1999aee5-40f7-609a-4d39-7e6fcf0d5041
Medical Dictionary...ory Activities ID	http://purl.bioontology.org/ontology/MDRFRE/10008915
Medical Dictionary...ory Activities ID	10008915
ICD-9 ID	571.4
skos:altLabel	Chronic liver inflammation (en) Recurrent hepatitis (en) гепатит хронічний (uk)
UMLS CUI	wds:Q62019625-e93b3d56-4866-8b23-a647-acbad40ebe1b
MeSH descriptor ID	wds:Q62019625-18b84634-4c0c-01b3-28cd-8431ac69b987
MeSH tree code	wds:Q62019625-68c57e5a-488c-79e5-05c1-adfdc91f136b
ICD-11 ID (MMS)	wds:Q62019625-00D57C5C-E971-437F-97E3-68F361DB9469
ICD-11 (foundation)	wds:Q62019625-43022E2E-494E-4DE1-BF94-B290C296F8B7
MeSH descriptor ID	http://id.nlm.nih.gov/mesh/D006521
MeSH tree code	http://id.nlm.nih.gov/mesh/C06.552.380.350
UMLS CUI	C0019189
MeSH descriptor ID	D006521
MeSH tree code	C06.552.380.350
ICD-11 ID (MMS)	DB97.2
ICD-11 (foundation)	1867966588
is field of work of	Stefan Zeuzem Thierry Poynard
is field of work of	wds:Q43252014-3A377C26-4A83-4345-BF7A-20A1D35A1F05 wds:Q28360321-FD6DFAB0-96E0-47DC-BD61-C2AC16334FF9
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q62019625 https://uk.wikipedia.org/wiki/%D0%A5%D1%80%D0%BE%D0%BD%D1%96%D1%87%D0%BD%D0%B8%D0%B9_%D0%B3%D0%B5%D0%BF%D0%B0%D1%82%D0%B8%D1%82
is main subject of	Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action New loci associated with chronic hepatitis B virus infection in Han Chinese Association between reactive oxygen species and disease activity in chronic hepatitis C IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Adaptive immune responses in acute and chronic hepatitis C virus infection Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers Liver-directed gamma interferon gene delivery in chronic hepatitis C. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules A pilot study of ribavirin therapy for chronic hepatitis C Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C Combination treatment with interferon and ribavirin for chronic hepatitis C. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection Drug treatment of pediatric chronic hepatitis B. The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy Effect of hepatitis G virus infection on chronic hepatitis C. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study Histopathologic impact of GB virus C infection on chronic hepatitis C. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus Antiviral action of ribavirin in chronic hepatitis C.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software